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guide$ decision$ making$ processes$ (GarclaVAltes$ et$ al.,$ 2004).$ Whilst$ reviews$ of$
economic$evaluations$of$pharmacological$treatments$for$schizophrenia$have$been$
conducted$ (Achilla$ and$McCrone,$ 2013),$ there$ has$been$no$ review$of$ economic$
evaluations$of$psychological$interventions$in$this$area.$This$review$addresses$this$
gap$by$examining$trialVbased$economic$evaluations$of$psychological$interventions$
for$ psychosis.$ Studies$ were$ identified$ from$ a$ systematic$ search$ across$ major$
electronic$databases$in$June$2017.$Eight$eligible$studies$were$identified.$Whilst$two$




confirmed$ in$ larger,$ more$ robust$ trials.$ The$ current$ evidence$ does$ not$ support$
Metacognitive$training,$Cognitive$Remediation$Therapy$or$Adherence$Therapy$as$
being$ costVeffective$ options.$ The$ overall$ small$ study$ number,$ diversity$ across$
studies$ and$methodological$ limitations$mean$ that$ the$ conclusions$ of$ this$ review$
should$be$considered$preliminary.$Emerging$results$are$nevertheless$promising$and$
















Despite$ its$ low$ lifetime$ prevalence$ (4/1,000$ peopleZ$ Saha$ et$ al.,$ 2005),$
schizophrenia$ and$ related$ psychotic$ disorders$ pose$ a$ considerable$ economic$
burden$to$healthcare$systems$(Mangalore$&$Knapp,$2007)$as$well$as$ to$ families,$
other$ caregivers,$ and$ wider$ society$ (Knapp,$ 2000Z$ Chong$ et$ al.,$ 2016).$
Schizophrenia$leads$to$high$direct$and$indirect$costs$with$estimates$of$direct$costs$
in$Western$countries$ranging$from$1.6%$to$2.6%$of$total$health$care$expenditures$








decisions.$ However,$ economic$ evaluations$ of$ psychological$ interventions$ for$
psychosis$are$rare$(Patel$et$al.,$2010).$Reviews$of$economic$evaluations$in$relation$
to$the$treatment$of$psychosis$have$been$restricted$to$pharmacological$studies$(e.g.$









natural$ units$ (e.g.$ changes$on$a$ symptom$severity$ scale)Z$ in$CUA$a$preferenceV
based$measure$of$health$ is$used$(such$as$qualityVadjusted$ life$years,$QALYs)Z$ in$
CBA$effects$are$measured$ in$monetary$units.$Together,$ they$are$considered$ ‘full’$
economic$evaluations$as$they$consider$both$the$costs$and$benefits$of$interventions$












June$ 2017:$ MEDLINE,$ EMBASE,$ PsychINFO$ and$ National$ Health$ Service$








Studies$were$ included$ if$ they$ reported$a$comparative$costVeffectiveness$analysis$









with$ those$ clearly$ not$ meeting$ inclusion$ criteria$ excluded.$ Where$ eligibility$ was$
unclear$based$on$title$and$abstract,$fullVtext$articles$were$reviewed.$Following$review$
                                                
1 A$decision$analytic$model$defines$a$set$of$mathematical$relationships$characterising$the$possible$


































































































health$ service,$ are$ included$ (Drummond$ et$ al.,$ 2015).$ In$ this$ instance,$ all$ direct$
medical$and$other$healthVrelated$costs$are$measured.$In$addition$to$these$costs,$the$
societal$perspective$also$ includes$ indirect$costs$such$as$ those$ relating$ to$ loss$of$
productivity.$$
$




with$ additional$ health$ care$ costs$ and$ is$ also$ less$ effective,$ it$ can$ be$ said$ to$ be$
dominated,$it$is$not$costVeffective.$If$an$intervention$offers$increased$health$benefits$
but$at$some$additional$cost$it$can$still$be$considered$costVeffective,$in$this$situation,$
the$ question$ of$ whether$ it$ should$ be$ regarded$ as$ costVeffective$ will$ depend$ on$
whether$decision$makers$consider$the$additional$cost$per$extra$unit$of$health$benefit$
worth$paying$for$(Drummond$et$al.,$2015).$The$most$common$approach$to$analysing$





must$ be$ compared$ to$ a$ specified$ monetary$ threshold$ which$ represents$ the$
maximum$amount$that$the$decision$maker$is$willing$to$pay$for$the$associated$health$
effect$(Fenwick$et$al.,$2006).$Within$the$UK,$the$preferred$measure$of$health$effect$
















graphs$ indicate$ the$ probability$ that$ the$ data$ are$ consistent$ with$ a$ true$ costV
effectiveness$ratio$falling$below$these$given$ceiling$amounts$(Haddock$et$al.,$2003).$
Where$CEACs$are$used,$conclusions$on$costVeffectiveness$can$be$given$greater$
weight$ (Fenwick$ et$ al.,$ 2006).$ The$ information$ provided$ by$ a$ CEAC$ and$ any$
statements$ made$ regarding$ them$ should$ be$ restricted$ to$ comments$ on$ the$
uncertainty$ of$ the$ estimate$ of$ costVeffectiveness$ rather$ than$ used$ to$ make$ any$





























Gaag$ et$ al.,$ 2011)$ and$ another$ recruited$ from$ an$ inpatient$ setting$ alone$ (van$




further$ study$ was$ conducted$ across$ sites$ in$ the$ UK,$ Germany,$ Italy$ and$ the$




two$studies$adopted$ the$health$and$social$ care$perspective$alone$ (Barton$et$ al.,$
2009Z$Priebe$et$al.,$2015).$
$
All$ studies$were$ conducted$across$multiple$ sites,$with$ one$ study$ involving$multiV
national$ sites$ (Patel$ et$ al.,$ 2013).$ Sample$ sizes$ varied,$ ranging$ between$ 36$












months.$ The$ psychological$ interventions$ considered$ included:$ Cognitive$
Behavioural$Therapy$ (van$der$Gaag$et$ al.,$ 2011Z$Barton$et$ al.,$ 2009),$CBT$with$
motivational$ intervention$ (Haddock$ et$ al.,$ 2003),$ Metacognitive$ training$ (van$
Oosterhout$ et$ al.,$ 2014),$ Adherence$ Therapy$ (Patel$ et$ al.,$ 2013),$ Cognitive$
Remediation$Therapy$(Patel$et$al.,$2010),$a$brief$intervention$informed$by$$SolutionV



















al.,$ 2015).$ In$ three$ out$ of$ the$ eight$ studies$ the$ competing$ alternatives$were$ not$
clearly$described$ (Patel$et$al.,$ 2013Z$Patel$et$al.,$ 2010Z$Zhang$et$al.$ 2014).$Two$
studies$did$not$adopt$an$appropriate$perspective$based$on$CHEC$criteria$(Barton$et$
al.$ 2009Z$Priebe$et$ al.2015).$Three$ studies$did$not$ complete$ sufficient$ sensitivity$





























































































































































































































































































































































































Another& study& compared& social& recovery& orientated& CBT& (SRCBT)& and& Case&
Management&Alone&(CMA).&Barton&et&al.&(2009)&found&that&costs&were&higher&in&the&
SRCBT&group&but& that&SRCBT&was&associated&with&better&outcomes,& i.e.&greater&







a& psychosocial& intervention& programme& which& included& psychoeducation,& family&
intervention,&skills&training,&CBT)&with&TAU.&CT&was&associated&with&more&QALYs&
gained.& Cost& differences&were& not& statistically& significant.& The& ICER& for& CT&was&








on&MANSA,&Manchester&short&assessment&of&quality&of& life)&and& that& it& therefore&





Haddock& et& al.& (2003)& considered& the& costGeffectiveness& of& CBT+Motivational&
Intervention&(CBT+MI)&compared&to&routine&care&(RC)&in&patientGcarer&pairs.&Patients&
met& diagnostic& criteria& for& substance& misuse& or& dependence& in& addition& to& a&
diagnosed& psychotic& disorder.& The& primary& outcome& for& the& CEA& was& Global&
assessment& of& functioning& (GAF)& score.& Results& indicated& that& CBT+MI& was&
associated&with&lower&costs&and&better&outcomes,&thereby&dominating&RC.&Based&on&
the& presented& CEAC,& the& probability& of& CBT+MI& being& costGeffective& when& the&
decision&maker&is&unwilling&to&pay&anything&additional&for&an&extra&point&increase&in&
the&GAF&was&69.3%.&If& the&decision&maker&was&prepared&to&pay&at& least&£30&per&








authors&acknowledged& is&an&unlikely&basis& for&choosing&a& treatment& (Patel&et&al.,&
 20 
2013).&Based&on&the&CEAC,&probabilities&of&AT&being&the&most&costGeffective&option&
ranged& between& 30& and& 60%& for& both& cost& perspectives& and& for& both& outcomes&
measured& (QALYs,& MCS& score)& for& the& willingness& to& pay& thresholds& examined&
(range& €0G5000).& Based& on& these& results,& AT&was& not& considered& to& be& a& costG
effective&treatment.&
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The&current& review&explored& the&costGeffectiveness&of&psychological& interventions&
for&people&with&psychosis.&This&is&the&first&known&review&of&economic&evaluations&in&





hypothetical& (i.e.& as& reported& in&CEACs),& or& indeed&are&not& reported&at& all.& Final&
interpretation& remains& subjective& and&will& depend& on& the& decision&maker.&Whilst&
methodological& differences& and& a& lack& of& commonly& accepted& costGeffectiveness&









2013).& In& another& study,& CBT& was& associated& with& greater& costs& and& better&
outcomes& and& was& likely& to& be& more& costGeffective& than& TAU& as& long& as& the&
willingness&to&pay&for&an&additional&day&of&normal&functioning&gained&was&higher&than&
€47& (van& der& Gaag& et& al.,& 2011).& There& is& no& consensus& on& an& acceptable&
benchmark&threshold&in&relation&to&an&additional&day&of&normal&functioning&(van&der&
Gaag&et&al.,&2011).&The&critical& issue&that&will&determine&whether&this&treatment&is&











A& treatment& combining& several& psychological& treatment& approaches& was& also&
reported&to&be&costGeffective&as&the&ICER&reported&was&below&the&common&threshold&
accepted&in&China.&In&this&case&though,&Zhang&et&al.&(2014)&did&not&present&a&costG









































economic&evaluation,&although& it& should&be&noted& that& the&sample&size&was&very&
small.& An& intervention& that& combined& patientGcentred& assessment& with& SFT& also&
dominated& indicating& that& it&was&costGeffective&however& the&degree&of&uncertainty&
was&difficult& to& fully&assess&and&there&were&other& issues& in&relation&to& inadequate&






costGeffective& however& further& research& using& improved& methodology& and&
comparison&with&an&appropriate&costGeffectiveness&threshold&(in&the&case&of&van&der&





against& health& economics& standards& (see& Table& 2).& In& addition& to& some& of& the&




the&purposes&of& economic&evaluation& (van&der&Gaag&et& al.,& 2011).&The&use&of& a&
single,& generic& measure& such& as& the& QALY& allows& for& comparison& of& diverse&
healthcare& interventions& (Duarte&et&al.,&2017).&Half&of& the&studies& included& in& this&
review&used&QALYs.&In&the&studies&adopting&different&outcome&measures&(e.g.&GAF,&
days&functioning&in&the&normal&range,&working&memory)&it& is&not&possible&to&make&
comparisons& across& studies.& Whilst& there& is& an& established& costGeffectiveness&






is& the& perspective& often& recommended& within& the& wider& health& economics& field&
(Drummond&et&al.,&2015).&Indirect&costs&have&been&found&to&constitute&a&substantial&
proportion&of&the&costs&associated&with&schizophrenia&with&evidence&suggesting&that&







examples& of& variability& that& exist& between& different& countries& and& health& care&
systems&which&can&impact&on&how&research&is&conducted.&Cost&estimates&can&vary&
significantly&depending&on&the&perspective&adopted&(Drummond&et&al.,&2015=&Luyten&
et& al.,& 2016)& therefore& studies& adopting& different& perspectives& will& not& have&
comparable& results.& Given& the& indirect& costs& associated& with& schizophrenia,&
researchers& within& the& UK& may& wish& to& consider& measuring& costs& from& both&




















provided& insufficient& information& to& establish& whether& all& important& and& relevant&








interpretation& of& their& results& and& thereby& maximise& the& value& of& the& research.&
Greater& consistency& and& transparency& in& reporting& should& also& allow& for&

















eligibility& or& data& extraction,& with& quality& ratings& the& only& aspect& of& the& review&
independently&assessed.&Finally,&whist&an&assessment&of&the&methodological&quality&
of& the& economic& evaluations& was& completed,& this& review& did& not& appraise&
methodological& quality& or& risk& of& bias& associated& with& the& RCTs& to& which& the&




country.& Differences& in& health& care& systems& in& terms& of,& for& example,& costs& and&
willingness&to&pay&thresholds,&mean&that&it&is&not&always&possible&to&generalise&the&











Despite& the& importance&of&economic&evaluation& for& resource&allocation&decisions,&














further& elucidate& their& potential& costGeffectiveness& and& will& help& commissioners&
allocating& scare&health& resources& to& consider& their& added& value& in& terms&of& their&
potential& to& deliver& better& outcomes& and& costGoffsets& in& comparison& to& other&
treatment&options&for&psychosis.&In&guiding&the&commissioning&and&design&of&more&

































































costGeffectiveness& acceptability& curves:& an& example& using& data& from& a& trial& of&
management& strategies& for& atrial& fibrillation.&BMC!health! services! research,&6(1),&
p.52.&
&
























Lutgens,& D.,& Gariepy,& G.& and& Malla,& A.,& 2017.& Psychological& and& psychosocial&
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Angermeyer,&M.,&Kikkert,&M.,&Schene,&A.&and&Knapp,&M.,&2013.&CostGeffectiveness&
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Stant,& A.D.& and& van& der& Gaag,& M.,& 2014.& Metacognitive& group& training& for&
















































wider& society.& Depression& is& common& in& people& with& psychotic& disorders& and&





with& a& diagnosis& of& schizophrenia& who& also& met& diagnostic& criteria& for& major&
depression.& The& trial& was& undertaken& by& a& group& of& researchers& in& Glasgow& in&
2014/15.&ACT&aims&to&help&people&relate&to&difficult&thoughts&and&feelings&in&more&
adaptive&ways&and&helps&them&to&commit&to&behavioural&change&that&is&consistent&
with& personally& held& values.& The& ADAPT& trial& included& 29& participants,& with& 15&
people&receiving&ACTdp&and&14&people&receiving&Standard&Care&(SC).&Data&were&




























health& and& social& care& services& in& this& group.& Whilst& there& was& no& significant&
difference& between& the& groups& in& terms& of& QALYs,& the& data& suggested& a& trend&





2015.&Methods! for! the! economic! evaluation! of! health! care! programmes.& Oxford&
university&press.&
&
Gumley,& A.,& White,& R.,& Briggs,& A.,& Ford,& I.,& Barry,& S.,& Stewart,& C.,& Beedie,& S.,&
McTaggart,& J.,&Clarke,&C.,&MacLeod,&R.,& Lidstone,&E.,&Riveros,&B.,&Young,&R.,&&&



























to& costGeffectiveness& of& ACTdp& and& to& consider& the& feasibility& of& conducting& an&
economic& evaluation& alongside& a& larger,& definitive& trial.& CostGeffectiveness& was&
explored&in&a&costGutility&analysis&(CUA)&with&qualityGadjusted&life&years&(QALYs)&as&
the&primary&outcome.&QALYs&were&calculated& from& the&EuroQol& (EQG5DG5L)&and&




































2002).& Depression& contributes& to& poorer& quality& of& life& in& people& with& psychosis&
(Connell&et&al.,&2014=&Saarni&et&al.,&2010)&and&is&associated&with&poorer&outcomes&
(Vorontsova& et& al.,& 2013)& and& greater& health& care& use& (Steel& et& al.,& 2015).&
Schizophrenia&comorbid&with&depression& is&also&associated&with&a&suicide&rate&of&
approximately&5%&which&is&significantly&higher&than&the&general&population&(Palmer&
et& al.,& 2005=&Hor& and&Taylor& 2010).& The& need& to& develop& and& disseminate& costG





approach& which& incorporates& mindfulness& and& acceptance& techniques& to& help&
people&relate&to&difficult&thoughts&and&feelings&in&more&adaptive&ways&and&helps&them&
to& commit& to& behavioural& change& that& is& consistent& with& personally& held& values&
(Morris& et& al.,& 2013).&A& recent&metaGanalysis&which& focused& on&mindfulness& and&
acceptanceGbased& therapies& for& psychosis,& including& ACT,& showed& small& to&
 36 
moderate&effect&sizes&when&compared&with&a&control&condition&(Khoury&et&al.,&2013).&
Randomised& controlled& trials& have& also& shown& that& ACT& can& lead& to& reduced&
depression&in&nonGpsychotic&populations&(Hacker&et&al.,&2016).&In&a&feasibility&study&
of&ACT&for&emotional&dysfunction&following&psychosis,&White&et&al.&(2011)&found&that,&
relative& to& a& group& receiving& treatment& as& usual& (TAU),& a& significantly& greater&
proportion&of&those&who&received&ACT&changed&from&being&depressed&at&baseline&
to&not&being&depressed&at&3Gmonth&followGup.& In&a&post&hoc&analysis,&White&et&al.&
(2015)& found& that& those& receiving& ACT& were& 15& times& more& likely& to& achieve& a&
clinically&significant&improvement&in&depression&scores&than&those&receiving&TAU.&&
ADAPT!trial!
















In& the& context& of& resource& constraints,& decision& makers& increasingly& rely& on&
economic& evaluations& to& guide& decision& making& processes& (GarclaGAltes& et& al.,&
2004)&and&are&increasingly&asking&economic&as&well&as&clinical&questions&in&relation&
to& new& treatment& developments& (Knapp,& 2000).& Where& there& are& competing&
healthcare& interventions,& economic& evaluation& informs& policymakers,& payers& and&
others&on&how&to&make&efficient&allocation&decisions&(Luyten&et&al.,&2016).&Although&






people&with&depression& in& the&context&of&psychosis,& the&question&of&whether& this&
treatment&can&be&considered&costGeffective&remains&unexplored.&There&are&currently&
three&preferred&methods&of&economic&evaluation:&costGbenefit&analysis&(CBA),&costG
effectiveness& analysis& (CEA)& and& costGutility& analysis& (CUA)& (Drummond& et& al.,&
2015).&All&three&subtypes&may&be&referred&to&as&costGeffectiveness&analyses&in&the&
literature.&&These&approaches&vary&in&the&effect&measure&employed.&In&CEA,&effects&
or& benefits& are& expressed& in& natural& units& (e.g.& changes& on& a& symptom& severity&
scale)=& in& CUA& a& preferenceGbased&measure& of& health& is& used& (such& as& qualityG
adjusted& life& years,& QALYs)=& in& CBA& effects& are& measured& in& monetary& units&









































Individuals& received& up& to& five& months& of& individual& ACTdp+Standard& Care&
(hereafter&referred&to&as&ACTdp).&The&intervention&has&been&described&elsewhere&

































perspective& preferred& by& NICE& (i.e.& ‘health& and& social& care& perspective’)& which&
























small& sample& size&of& this& study&and& the& tendency& for& cost& data& to& have&a&highly&
skewed&distribution&(Briggs&and&Gray,&1998),&differences&between&total&costs&will&not&










hypothesisGgenerating& only.&NICE& suggest& that,& in& general,& interventions&with& an&























At&baseline,&data&were&available& for&all&participants& in& relation& to&service&use&and&
quality&of&life.&Two&participants&in&the&ACtdp&group&declined&followGup&at&5Gmonths&
with& a& further& participant& lost& to& followGup& at& 10Gmonths& (total& n=3).& Data& were&
available&for&all&participants&in&the&SC&group&at&5Gmonths&with&one&declining&followG






















there& were& further& observable& differences& in& service& use& and& associated& costs&
                                                
2 This was completed by Bruno Riveros prior to the transfer of data to the writer 
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group.& Between& baseline& and& 5Gmonths,& the& difference& in&CPN& use& observed& at&
baseline&appeared&to&lessen&with&service&use&and&associated&cost&now&also&slightly&
higher&in&the&SC&group&(4971&hours,&£294.71)&than&in&the&ACTdp&group&(4013&hours,&
£222.05).&Contact&with&Social&Work&was&also&observed& to& increase& in& the&ACtdp&




































SC& ACTdp& SC& ACTdp& SC& ACTdp&
Service! Total&& Pts&& Total& Pts& Total& Pts& Total& Pts& Total& Pts& Total& Pts&
Psychiatric&
ward&(days)&









1& 1& 8& 1& 2& 2& 1& 1& 5& 3& 0& 0&
CMHT&
(hours)&


















0& 0& 60& 1& 330& 2& 360& 1& 600& 2& 210& 2&
CPN&
(mins)&




0& 0& 90& 1& 80& 1& 1,490& 3& 0& 0& 245& 1&
OT&
(mins)&
60& 1& 1,870& 3& 295& 3& 185& 2& 135& 2& 462& 1&
Chiropodist&
(mins)&
0& 0& 85& 3& 0& 0& 140& 2& 30& 1& 20& 1&
GP&
(mins)&
230& 9& 370& 10& 415& 10& 170& 6& 354& 8& 35& 4&
Dentist&
(mins)&
90& 5& 205& 8& 140& 6& 96& 5& 280& 7& 255& 5&
Optician&
(mins)&




G& & G& G& 0& 0& 36,570& 15& G& & G& &
Medication& G& 14& G& 14& G& 14& G& 14& G& 13& G& 11&
GP:&General&Practitioner,&CPN:&Community&Psychiatric&Nurse,&CMHT:&Community&
Mental&Health&Team,&OT:&Occupational&Therapist,&appt:&appointment,&mins:&minutes&
















SC& ACTdp& SC& ACTdp& SC& ACTdp&








































































































































































G& G& G& 2,511.14&
[1,080]&
G& G&















! SC& ACTdp& Difference&














! Baseline& & 5Gmonths& 10Gmonths&

























                                                






SC! 0.477& 0.224& 0.019& 0.754&



















0.481& 0.091& 5.288& 0.000& 0.294& 0.667&
Group! 0.045& 0.052& 0.868& 0.394& G0.062& 0.152&
&
CostGeffectiveness!!
The&numerical& trends& in& the&data& indicate& that&ACTdp& is&associated&with&greater&
costs& but& also& better& outcomes.& Whilst& differences& in& costs& were& not& explored&
statistically&and&there&was&not&a&significant&difference&between&the&groups&in&terms&










A& costGeffectiveness& plane& was& plotted& (Figure& 1)& which& shows& the& ICER& point&
estimate& along&with& 95%& confidence& intervals& for& costs& and& effects.& Two& ceiling&
ratios&(£20,000&and&£30,000),&i.e.&the&maximum&values&that&a&decision&maker&might&
be&willing&to&pay&for&an&additional&QALY,&were&added.&Whilst&the&confidence&intervals&


































Due& to& the& pilot& nature& of& this& trial,& making& any& firm& conclusions& about& costG
effectiveness&of&ACTdp&from&this&evaluation&would&be&premature.&It&is&not&possible&




treatment& as& usual& (TAU)& had& half& the& rate& of& rehospitalisation& than& that& of&
participants&receiving&TAU&over&a&4Gmonth&period&(Bach&et&al.,&2012).&Inpatient&care&
is& the&most&costly&component&of&healthcare& in&the&overall& treatment&of&psychosis.&
Knapp&et&al.&(2000)&consulted&evidence&from&a&number&of&countries&and&reported&









Uncertainty& surrounds& estimates& of& effectiveness,& costs& and& the& resulting& costG
effectiveness& ratios& (Edejer,& 2003).& As& ICERs& are& pointGestimates,& they& do& not&
capture&uncertainty&in&the&sample&data&on&which&they&are&based&(Miller&et&al.,&2003).&









the&overall& objectives&of& the&pilot& trial&which& included&confirming& the& feasibility&of&



















al.,& 2014),&Cognitive&Remediation&Therapy,&CRT& (Patel& et& al.,& 2010),&Adherence&
Therapy,&AT,&(Patel&et&al.,&2013),&a&brief&intervention&informed&by&Solution&Focused&
Therapy& (SFT)& alongside& patientGcentred& assessment& (Priebe& et& al.,& 2015)& and&
Metacognitive&training&(van&Oosterhout&et&al.,&2014).&&
&
From& the& studies& referred& to& above,& there& were& two& instances& where& the&


















generalisable& to&other& study& locations&or& different& health& service& contexts&due& to&
potential& differences& in& costs& and& service& use& patterns.& Some& participants& also&
declined&(n=3)&or&were&lost&to&followGup&(1),&the&reasons&for&which&are&not&clear&at&
this& stage.& Positively& however,& no& one& in& the& ACTdp& group& dropped& out& during&
treatment& suggesting& that& ACTdp& is& a& well& tolerated& intervention.& The& low&
cancellation&and&nonGattendance&rates&further&confirm&this&(Gumley&et&al.,&2017).&&
&
As&stated&earlier& in& this&paper,&NICE& (2012)& recommend& that& the&perspective&on&
costs&should&be&that&of&the&NHS&and&Personal&Social&Services,&PSS&(i.e.&‘health&and&
social&care’&perspective).&They&also&specify&that&if&broader&costs&must&be&included&





which& are& incurred& directly& by& the& health& service& alone& (Davies& and&Drummond,&
1994=&Knapp,&2000=&Mangalore&and&Knapp,&2007).&One&recommendation&for&future&
research&may& therefore&be& to&capture&costs& from&both&a&societal&and&health&and&
social& care& perspective& and& to& explore& the& impact& of& adopting& the& differing&
perspectives& on& resulting& ICERs& and& conclusions.& This& may& elucidate& whether,&
despite&NICE& recommendations,& research& in& relation& to&psychosis&should& indeed&
incorporate&broader& cost& categories&within& the&costGeffectiveness&analyses.&Also,&
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given&that&ACT&aims&to&enhance&engagement&with&valued&life&activities,&rather&than&


















personal& suffering& and& reduced& quality& of& life& and& are& also& associated& with& a&
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Y: yes; N: no; NA: Not applicable a: van Oosterhout et al. (2014); b: van der Gaag et al. 
(2011); c: Barton et al. (2009); d: Patel et al. (2013); e: Patel et al. (2010); f: Priebe et al. 
(2015); g: Zhang et al. (2014); h: Haddock et al. (2003) 
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10Gmonths.& Healthcare& and& other& service& costs& will& be& estimated& by& multiplying&
resource&use&by&the&appropriate&unit&cost.&This&will&allow&differences&to&be&described&
between& the& ACTdp& and& SC& groups& in& service& utilisation& and& associated& costs.&
Health& economic& analysis& focused& on& quality& of& life& outcomes& and& the& costs& of&





complex& mental& health& problems& can& be& evaluated& from& a& health& economic&








Schizophrenia& and& related& psychotic& disorders& are& among& the& most& disabling&
illnesses& worldwide& (World& Health& Organization=& WHO,& 2001)& and& pose& a&
considerable&economic&burden&to&healthcare&systems&(Mangalore&&&Knapp,&2007=&
Stant& et& al.,& 2007).& Despite& its& low& lifetime& prevalence& (median& 4.0& per& 1,000&
persons=& Saha& et& al.,& 2005),& health,& social,& and& economic& burden& related& to&
schizophrenia& is& significant,& not& only& for& patients& but& also& for& families,& other&
caregivers,&and&wider&society&(Chong&et&al.,&2016).&The&World&Health&Organization&
(WHO)&estimated& that&direct& costs&of& schizophrenia& in&Western&countries& ranges&
from&1.6%&to&2.6%&of&total&health&care&expenditures&(Barbato&et&al.,&1998).&
&
Clinical&depression& is& the&second& largest&cause&of&global&disability& (Ferrari&et&al.,&
2010).& Globally,& the& drag& effect& of& depression& on& aggregate& economic& output& is&








an&acute&episode& in&up& to&30%&of&cases& (Siris,&1995).&Depression&contributes& to&
poorer&quality&of&life&(Saarni&et&al.,&2010)&and&is&associated&with&poorer&outcomes&in&




An& analysis& of& the& comparative& effectiveness& and& costs& of& pharmacological& and&
psychosocial& interventions& for& reducing& the& burden& of& mental& disorders& (WHO,&
2006a)&concluded&that&there&are&modest&extra&costs&(for&training&and&intervention)&
of&providing&psychosocial&treatment&alongside&pharmacological&treatment&for&severe&
mental& disorders& such& as& schizophrenia& and& bipolar& affective& disorder& but& that&




treatments&are&numerous&and& include&not& only& reduced&psychiatric&morbidity&but&




(Wykes& et& al.,& 2008)& interventions& for& depression& in& people& diagnosed& with&
schizophrenia& (Gumley&et& al.,& 2017).&Although& there& is&preliminary&evidence& that&
depression& symptoms& improve& in& people& receiving& CBT& for& psychosis& (CBTp)&




intervention& that& helps& individuals& to& disengage& from& unhelpful& coping& strategies&
including& rumination& and& avoidance& and& enables& them& to& commit& to& behavioural&
change& consistent& with& personally& held& values& (Gumley& et& al.,& 2017).& There& is&
preliminary& evidence& of& clinical& and& costGeffectiveness& of& ACT& when& delivered&
individually& to&people&with&psychosis&(Johns&et&al.,&2015).&Randomised&controlled&
trials&have&also&shown&that&ACT&can&lead&to&reduced&depression&in&nonGpsychotic&
populations& (Hacker& et& al.,& 2016).& In& a& feasibility& study,& White& et& al.& (2011)&
investigated& ACT& for& psychosis& with& the& primary& outcome& focused& on& emotional&
distress.&They&found&a&trend&on&the&limit&of&significance&for&differences&between&the&
groups&in&depression&(p=0.051)&(White&et&al.,&2011).&In&a&later&analysis,&White&et&al.&
(2015)& found& that& ACT& was& associated& with& significantly& greater& likelihood& of&
achieving&a&clinically&significant&improvement&in&depression.&&
&
The& ADAPT& trial& was& a& pilot& randomised& controlled& trial& of& Acceptance& and&
Commitment&Therapy&for&depression&after&psychosis&(ACTdp)&for&individuals&with&a&
diagnosis& of& schizophrenia& who& also& met& DSMGIV& diagnostic& criteria& for& major&
depression.&This&trial&followed&the&feasibility&study&conducted&by&White&et&al.&(2011)&
described&above.&An&additional&aim&of&the&ADAPT&trial&was&to&capture&data&that&could&
be& used& to& assess& the& costGeffectiveness& of& ACTdp& –& an& increasingly& important&













offsets& the& additional& cost& of& providing& the& treatment.& In& the& context& of& resource&
scarcity&which&is&inherent&within&any&healthcare&system,&health&economic&evaluation&
has&been&developed&as&a&methodology&to&inform&policymakers,&payers&and&others&
on& how& to& make& efficient& allocation& decisions& over& competing& healthcare&



























instrument& that& has& been& successfully& used& with& people& diagnosed& with&
schizophrenia& and& can& be& used& to& calculate& quality& adjusted& life& years& for& the&



































CSRI& and& healthGrelated& quality& of& life& data& were& collected& at& entry& preG
randomisation,&5Gmonths&and&10Gmonths&by&a&Research&Assistant&who&was&masked&
to&treatment&allocation.&Healthcare&and&other&service&resource&use&data&relates&to&


















al.,&2017).&QALYs&are&an&overall&measure&of&health&outcome& that&weight& the& life&
expectancy& of& a& patient& with& an& estimate& of& their& healthGrelated& quality& of& life&
(measured&on&a&0–1&scale)&(NICE,&2012).&CostGeffectiveness&analysis&with&the&units&
of&effectiveness&expressed&in&cost&per&QALY&gained&(cost–utility&analysis)&is&widely&
recognised& as& a& useful& approach& for&measuring& and& comparing& the& efficiency& of&
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The&economic&evaluation&will& take& the&NHS&and&Personal&Social&Services& (PSS)&
perspective&preferred&by&NICE&(NICE,&2012).&From&the&CSRI&data,&service&utilisation&
costs&will&be&estimated&by&multiplying&the&resource&use&by&the&appropriate&unit&cost,&
using& routinely& published&UK& unit& cost& estimates& (pounds& sterling& at& 2014–2015&
prices).&Information&on&unit&costs&will&be&obtained&from&national&list&prices&such&as&
the&PSSRU&(Personal&Social&Services&Research&Unit)&Unit&costs&of&health&and&social&
care& and/or& Department& of& Health& reference& costs,& inGline& with& NICE&
recommendations&(NICE,&2012).&Intervention&costs&will&be&calculated&using&available&













CostGeffectiveness&will& be& assessed& through& the& calculation& of& incremental& costG
effectiveness& ratios& (ICERs)&and&will&be&explored& in& terms&of&cost&utility&by&using&
QALYs&as&the&measure&of&effect,&as&derived&from&the&EQG5DG5L.&Uncertainty&around&





the& ICER,& including& in& circumstances& where& statistical& power& limits& significance&
testing&(Briggs,&2000).&CostGeffectiveness&planes&will&indicate&the&probability&that&the&
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intervention& is& (i)& cost& saving& with& better& outcomes=& (ii)& cost& saving& with& worse&




























will& report& will& contribute& to& this& broader& framework& of& evidence& and& our&
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The& following& proposal& relates& to& a& major& research& project& which& was& initially&
undertaken& prior& to& the& project& which& has& been& presented& in& this& portfolio.& This&
project&was&developed&to&the&point&of&study&commencement&and&recruitment.&The&
ethics& application& process& was& completed& and& approval& received.& & However,&
difficulties& with& recruitment& over& January& –& April& 2017& led& to& the& project& being&
terminated.&The&intention&had&been&to&recruit&15&participants&for&this&feasibility&study&
however& by& April& 2017,& only& one& potential& participant& was& eligible& based& on&
screening&questions.&Other&potential&participants&who&had&expressed&an&interest&in&
taking&part&in&the&research&did&not&meet&inclusion&criteria.&In&order&to&be&able&to&meet&
the& research&portfolio& requirements,& it&was&necessary& to& undertake&a& new&Major&

















Between& 50G74%& of& dementia& carers& report& some& sleep& disturbance& (Peng& and&
Chang,& 2013)& however& relatively& few& studies& have& explored& interventions& for&






























Approximately& one& third& of& the& general& population& presents& with& at& least& one&
insomnia&symptom,&such&as&difficulty&with&sleep&initiation&or&maintenance&(Ohayon,&
2002).& In& the&UK,& the&results&of& the&Great&British&Sleep&Survey&(GBBS)& indicated&
that,&of&11,129&participants&who&completed&the&GBSS&between&March&2010&and&April&




2013).& Dementia& carers& may& be& particularly& at& risk& for& suffering& negative&





2011=& Peng& and& Chang,& 2013).& Sleep& disturbance& associated& with& caring& for&




Cognitive& Behavioural& Therapy& for& Insomnia& (CBTI)& is& currently& the& first& line&
psychological& treatment& for& insomnia& and& has& been& shown& to& be& equal& to&
pharmacotherapy& during& acute& treatment& and& more& effective& in& the& long& term&
(Reimann,& 2015).& Efficacy& has& been& reported& for& individually& delivered& CBT& for&










Relatively& few& studies& have& explored& interventions& for& dementia& carers& where&
insomnia&symptoms&have&been&the&primary&focus&of&intervention,&however,&findings&
from&research&to&date&are&promising&(McCurry&et&al.,&2015).&McCurry&et&al.&(1998)&




management& and& also& guidance& in& relation& to& the& management& of& behaviour&
problems&in&the&person&with&dementia&(McCurry&et&al.,&1998).&&
&
In& another& study,& a& brief& behavioural& intervention&delivered& to& a& small& sample&of&
carers&of&both&communityGdwelling&and& institutionalized& individuals&with&dementia&
indicated&a&trend&towards&improvement&in&sleep&quality&and&depression&(Simpson&







based&on& the&same&core&principles&which&are&key& to&other&empirically& supported&
treatments,&including&CBTI&(Troxel&et&al.,&2012).&The&basic&rationale&for&BBTI&is&that&
it& is&possible&to&have&a&direct& impact&on&the&two&major&physiological&systems&that&





Several&studies&support& the&use&of&BBTI& to& treat& insomnia.&Germain&et&al.& (2006)&
randomly&assigned&35&older&adults&to&BBTI&or&an&information&only&control.&At&4&weeks&
postGintervention,&significant&improvements&in&sleep&diary&and&self&report&measures&




In& a& recent& clusterGrandomized& controlled& trial,& Fuller& et& al.& (2015)& tested& the&
feasibility&of&modified&BBTI&delivered&by&pharmacists&(Fuller&et&al.,&2015).&They&found&
a&significant&decrease& in& Insomnia&Severity& Index&(ISI)&scores& from&baseline& to&3&
month&followGup&in&the&intervention&group&(nG17)&relative&to&controls&(n=19).&Although&
the& difference& in& ISI& between& intervention& versus& controls& was& not& found& to& be&
significant&when&cluster&effects&were& taken& into&account,& the&results&nevertheless&
indicated& that& reductions& in& insomnia& severity& can& be& gained& using& nonGsleep&
professionals&to&deliver&a&brief&behavioural&intervention&(Fuller&et&al.,&2015).&&
Relatively& few& studies& have& explored& interventions& for& dementia& carers& where&










As& stipulated& in& the&Medical& Research& Council& (2008)& guidelines& on& developing&
complex& interventions,& the& feasibility& and& piloting& stage& includes:& estimating& the&
likely&rates&of&recruitment&and&retention&of&participants,&testing&procedures&for&their&
acceptability& and& calculation& of& appropriate& sample& sizes.& Based& on& these&
guidelines,&the&current&study&aims&to&explore&how&many&eligible&participants&consent&
to& participate,& how& many& are& retained& and& whether& the& adapted& intervention& is&
acceptable.&The&study&will&also&explore&outcomes&on&a&range&of&measures&and&report&




































being& investigated& for& a& degenerative& condition.& In& order& to& be& as& inclusive& as&
possible,&carers&who&have&previously&had&a&stroke&will&not&be&excluded.&In&instances&
where&a&potential&participant&has&had&a&stroke,&consent&will&be&requested&to&consult&











The& Pittsburgh& Sleep& Quality& Index& (PSQI)& was& deemed& the& most& appropriate&
measure&upon&which&to&base&the&sample&size&calculation&due&to&its&coverage&of&a&
number&of&relevant&sleep&variables.&To&our&knowledge,&only&two&studies,&those&by&
McCurry& et& al.& (1998)& and& Simpson& and& Carter& (2010)& described& earlier,& have&





the&PSQI&was& large& (d=0.9).& Using& this& effect& size& (d=0.9),& power& of& 0.8,& and& a&
significance&level&of&0.05,&the&sample&size&required&is&estimated&to&be&11.&Given&that&
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some& participants&may& withdraw& from& the& study& or& not& be& able& to& complete& the&
intervention,&the&study&will&aim&to&recruit&15&participants.&Whilst&the&measurement&of&






those& locations.& However,& a& number& of& potential& barriers& to& recruitment& were&














facilitators& would& impose& difficulties& in& terms& of& delivering& all& aspects& of& the&
intervention& adequately& and& in& terms& of& providing& adequate& support& to& each&
individual&during&the&sessions.&Assessment&measures&will&be&completed&at&baseline&
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and& immediately& post& treatment& with& sleep& diaries& being& kept& throughout& the&
intervention.&&FollowGup&assessment&will&be&undertaken&at&4&weeks&postGtreatment.&
Both&those&who&complete&BBTI&and&those&who&do&not&will&be&invited&to&attend&a&focus&
group& for& the& purposes& of& exploring& acceptability& of& treatment& and& the& study&
procedures&in&general.&The&flow&chart&in&Figure&1&outlines&the&research&procedure.&
In& order& to& reduce& disruption& to& carers’& normal& routine& and& caregiving&
responsibilities,&initial&screening&will&be&conducted&via&telephone&in&order&to&assess&
whether& they& meet& inclusion& criteria.& & Thereafter,& if& assessed& as& safe& to& do& so&
following& consultation& with& the& Older& People’s& Community& Mental& Health& Team,&
baseline&assessment&will&be&completed&at&the&participant’s&home,&again,&to&reduce&
burden&on&the&caregiver.&In&any&instance&where&risk&associated&with&completing&a&















The& principal& researcher& will& complete& the& telephone& screening& and& all&





























Drug& and& alcohol& information:&Alcohol&Use&Disorders& Identification& Test& (AUDIT,&
Bohn&et&al.,&1995)=&Drug&Use&Disorders&Identification&Test&(DUDIT,&Berman&et&al.,&
2005)&




Condition& Indicator& (SCI,& Espie& et& al.,& 2014)=& Stanford& Sleepiness& Scale& (SSS,&








those&who&completed&and&did&not&complete&BBTI&will&be& invited& to& take&part& in&a&
focus&group,&the&primary&aim&of&which&will&be&to&explore&aspects&of&acceptability&such&





A& statistician& will& be& consulted& prior& to& finalising& the& analysis& plan.& Descriptive&
statistics&will&be&reported.&It&is&anticipated&that&a&withinGsubjects&tGtest&will&be&used&to&
explore& changes& in& the& primary& variable& of& interest,& namely& sleep& quality& as&
measured&by& the&PSQI.& In& the&event& that&parametric&assumptions&are&not&met,&a&
Wilcoxin&test&will&be&performed.&
Settings!and!equipment&
Groups& and& faceGtoGface& assessment& will& take& place& within& the& Argyll& Centre& or&













restriction& strategies& (Troxel& et& al.,& 2012).& Specific& guidance& will& be& given& to&
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participants&regarding&this&prior&to&them&giving&consent.&Assessment&of&the&severity&







they& require& further& support,& will& be& signposted& to& their& GP.& If& issues& arise& that&
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